Institut universitaire du cancer de Toulouse Oncopole

Recent papers from Institut universitaire du cancer de Toulouse Oncopole

1. A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM DatabaseClinical Pharmacology & Therapeutics · 2026
2. Isolated Cephalic Perfusion via Aortic Occlusion for Cervicofacial Simulation: Validation of a High‐Fidelity Cadaveric ModelOtolaryngology · 2026
3. Palliative systemic chemotherapy in peritoneal mesothelioma: a retrospective efficacy analysis of the RENAPE databaseESMO rare cancers. · 2026
4. Salvage-free, transplantation-free survival: a proposal for a new clinical endpoint in acute myeloid leukemiaHaematologica · 2026
5. Prognostic Factors in Patients with Initial Low- and Intermediate-Risk Papillary Thyroid Carcinoma Who Undergo Revision Surgery Including the Central Neck CompartmentThyroid · 2026
6. The role of information and consent forms in patients’ decision-making regarding participation in oncology clinical trialsTrials · 2026
7. A deep-learning model based on histological images predicts survival and pathological response to neoadjuvant chemotherapy and chemoimmunotherapy in breast cancerJournal of Translational Medicine · 2026
8. Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trialCancer · 2026
9. Invisible shield: sprayable supramolecular antimicrobial microscale films for preventing wound and medical device infectionsnpj Biomedical Innovations. · 2026
10. 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trialNature Medicine · 2026
11. MEK inhibition in molecularly-selected advanced or metastatic solid tumours: final analysis of trametinib cohort from the platform phase II trial MegaMOSTBMC Cancer · 2026
12. Prognostic Impact of FLT3 ‐ ITD Allelic Ratio in AML Patients Treated With High‐Dose Anthracycline and a FLT3 InhibitorAmerican Journal of Hematology · 2026
13. Deep Dermatophytosis Associated With Inherited CARD9 Deficiency: Efficacy of Topical 1% VoriconazoleJEADV Clinical Practice · 2026
14. Hormone Receptor–Positive HER2-Negative Oligometastatic Breast Cancer: prognostic stratification and pattern of progressionThe Oncologist · 2026
15. PINK1-mediated mitophagy supports lung cancer initiation and limits the efficacy of KRAS -targeted therapyScience Advances · 2026
16. Hackathon on predictive modelling in systems pharmacology: design, implementation, and outcomesF1000Research · 2026
17. PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12Nature Communications · 2026
18. Oral Azacitidine Maintenance After CPX ‐351 in Transplant‐Ineligible Patients With Therapy‐Related or Myelodysplasia‐Related Acute Myeloid LeukemiaAmerican Journal of Hematology · 2026
19. Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT studyBlood Cancer Journal · 2026
20. Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trialPLoS ONE · 2026